Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer-GOG-3059

People with Platinum-Resistant Recurrent Ovarian Cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

You may be eligible to participate in this study if you:

  • Are a female at least 18 years of age
  • Have histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer
  • Have available archived tumor tissue
  • Received at least 1 but not more than 4 prior therapy regimens since ovarian cancer diagnosis
  • Have adequate bone marrow, hepatic, and renal function

You may NOT participate in this study if you:

  • Have tumors in the breast or bone
  • Have primary platinum-refractory disease
  • Are being treated with concurrent anticancer therapy or other interventional treatments
  • Have clinically significant cardiac disease history
  • Have ever participated in a study with AVB-S6-500
  • Have a serious active infection requiring IV antibiotics and/or hospitalization
  • Have known immunodeficiency virus (HIV) infection, hepatitis B, or C
  • Are pregnant or breastfeeding

Contact Information

Stephanie Blank, MD, Principal Investigator

One Gustave L. Levy Place, Box 1170 New York, NY 10029
Phone: (212) 604 6059
Fax: (212) 824 2347